Trademark: 98113572
Word
AUREALIS THERAPEUTICS
Status
Pending
Status Code
686
Status Date
Tuesday, August 13, 2024
Serial Number
98113572
Mark Type
4
Filing Date
Wednesday, August 2, 2023
Published for Opposition
Tuesday, August 13, 2024

Trademark Owner History
Aurealis Therapeutics AG - Owner At Publication

Classifications
5 Pharmaceutical and veterinary preparations, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; sanitary preparations for medical purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; dietetic food and substances, namely, fermented milk products, drinks and gum, adapted for medical or veterinary use; dietary supplements for humans and animals; health care products, namely, medical plasters, medical dressings, medicated ointments, medicated sprays, vaccine preparations, and human therapeutic agents for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; disinfectants; preparations for destroying vermin; fungicides and herbicides; pharmaceuticals, biosimilars, medicine, drugs, namely, immunomodulators and anticancer agents, antibodies, antibody fragments, checkpoint inhibitors and checkpoint modifiers, vaccines, for human beings and animals; prokaryotic organisms, namely, genetically modified bacteria, bacteria producing growth factors, antibodies, immunomodulators, anticancer agents, checkpoint inhibitors and checkpoint modifiers and vaccines for medical use; medicines for human purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; medicines for veterinary purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; bacteriological preparations for medical and veterinary use, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; biological preparations for medical purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; biological preparations for veterinary purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; chemical preparations for medical purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; chemical preparations for pharmaceutical purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; chemical preparations for veterinary purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; pharmaceutical and veterinary preparations and substances in particular for the treatment of cancer, inflammatory diseases, immune system related diseases, specifically autoimmune disorders, and other conditions which can be treated or ameliorated by antibodies or antibody fragments binding to, activating or blocking of a target antigen or ameliorated by immunomodulating factors, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer
"THERAPEUTICS"

Trademark Events
Aug 5, 2023
New Application Entered
Aug 7, 2023
New Application Office Supplied Data Entered
Apr 4, 2024
Non-Final Action Written
Apr 4, 2024
Non-Final Action E-Mailed
Jul 3, 2024
Teas/Email Correspondence Entered
Jul 3, 2024
Correspondence Received In Law Office
Jul 3, 2024
Teas Response To Office Action Received
Jul 8, 2024
Approved For Pub - Principal Register
Jul 24, 2024
Notification Of Notice Of Publication E-Mailed
Aug 13, 2024
Published For Opposition
Aug 13, 2024
Official Gazette Publication Confirmation E-Mailed
Apr 4, 2024
Notification Of Non-Final Action E-Mailed
Apr 3, 2024
Assigned To Examiner

Trademark Alertz updated from USPTO on 2030-01-24